The inhibitory effect of 50 mg/kg lysyl acetylsalicylic acid (ASA) intravenously injected 24 and 4 h before 80 μg/kg adrenaline, 40 mg/kg indobufen injected 15 min before, or a combination of ASA plus indobufen on the platelet aggregation and kinetics was evaluated in anaesthetized dogs previously injected with 111indium- (111In-) labelled platelets using γ-camera dynamics studies. The highest degree of inhibition, indicated by the lowest platelet aggregation ratio decrease and the most significant 111In-labelled platelet mobilization from hepatic and splenic stores with a corresponding increase of labelled and unlabelled platelet counts in blood, was obtained in ASA-treated dogs. Such changes were less marked when ASA plus indobufen was injected. In indobufen-treated dogs a similar mobilization of 111In-labelled platelets with an increase in circulating platelet numbers was evident only after the second adrenaline injection. It is concluded that platelet mobilization is mainly dependent on the production of an ASA-sensitive substance.
HammonJNOatesJAInteraction of platelets with the vessel wall in the pathophysiology of sudden cardiac death. Circulation1986; 73: 224–226.
2.
LewisHDDavisJWArchibaldDGProtective effects of aspirin against acute myocardial infarction and death in man with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med1983; 309: 396–403.
3.
FieldsWSLemakNAFrankowskiRFControl trial of aspirin in cerebral ischemia. Stroke1977; 8: 301–307.
4.
CollerBSPlatelets and thrombolytic therapy. N Engl J Med1990; 322: 33–42.
5.
GoldmanSCopelandJMoritzTSaphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy results of a Veterans Administration Cooperative Study. Circulation1989; 80: 1190–1197.
BornGVPolypharmacologic interactions in the management of thrombosis. Semin Thromb Haemost1988; 15: 140–143.
8.
MullerJEMorning increase of onset of myocardial infarction: implications concerning triggering events. Cardiology1989; 76: 96–104.
9.
HarkerLAClinical trials evaluating plateletmodifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. Circulation1986; 73: 206–223.
10.
ThakurMIWelchMJJoistJH111Indium labelled platelets: studies on preparations and evaluations of in vitro and in vivo functions. Thromb Res1976; 9: 345–357.
11.
SinzingerHKolbeHStrobl-JägerEA simple and safe method for sterile autologous platelet labelling using ‘Monovette’ vials. Eur Nucl Med1984; 9: 320–322.
12.
FalconCArnoutJVermylenJPlatelet aggregation in whole blood – studies with a platelet counting technique – methodological aspects and some applications. Thromb Haemost1989; 61: 423–428.
13.
WuKKSHoakJCA new method for the quantitative detection of platelet aggregates in patient with arterial insufficiency. Lancet1974; ii: 924–926.
14.
VermylenJWhat have we learned from large scale trials with antiplatelet drugs?Med Razgl1990; 29 (suppl 1): 111–123.
15.
DimsdaleJERubermanWCarletonRATask force I. Sudden cardiac death. Stress and cardiac arrhythmias. Circulation1988; 76 (suppl 1): 198–201.
16.
SimonsMDowningSECoronary vasoconstriction and catecholamine cardiomyopathy. Am Heart J1985; 109: 297–304.
17.
CoccheriSPalaretiGFibrinogen as a risk index and pathogenic factor for thrombosis. Med Razgl1990; 29 (suppl 1): 71–81.
18.
GrimandoVHauertJBachmanFDiurnal variations of the fibrinolytic system. Thromb Haemost1986; 59: 495–499.
19.
LanzaFBeretzAStierliAEpinephrine potentiates human platelet activation but is not an aggregation agent. Am J Physiol1988; 255: H1276–H1288.
20.
MillsDCRobertsGCKEffects of adrenaline on human blood platelets. J Physiol (Lond)1967; 193: 443–453.
21.
HolmsenHPhysiological functions of platelets. Ann Med1989; 21: 23–30.
22.
De GaetanoGCerlettiCDejanaECurrent issues in thrombosis prevention with antiplatelet drugs. Drugs1986; 31: 517–549.
23.
PatronoCAspirin and human platelets; from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci1989; 10: 453–458.
24.
LorenzRLBoehlingBUedelhovenWMSuperior antiplatelet action of alternative day pulsed dosing versus split dose administration of aspirin. Am J Cardiol1989; 64: 1185–1188.
25.
DaviGCatalanoISpatolaAEffect antipiastrinici della terapia combinata ticlopidina piu basse dosi di aspirina in pazienti con cardiopatia ischemia. Cardiologia1989; 34: 69–71.
26.
PintoASorrentinoRLevamisole in vivo rat platelet aggregation by release of prostacyclinlike factor. Gen Pharmacol1990; 21: 255–229.
27.
PintoAAbbateRFavillaSEx vivo and in vitro study of the effects of indobufen on endogenous and exogenous arachidonic acid metabolism by platelets. Curr Ther Res1987; 42: 243–252.
28.
CraveriAColomboLLanfrediniMEffect of indobufen on whole blood platelet aggregation recorded in the morning in patients with ischaemic heart disease. J Int Med Res1989; 17: 381–387.
29.
HoetBFalconCde ReysSA combined thromboxane synthase inhibitor inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. Blood1990; 75: 646–653.
30.
HirshPDHillisLDCampbellNBRelease of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med1981; 304: 685–691.
31.
ButtrickPMForcherCASussmanITSubaggregatory doses of catecholamines prevent prostacyclin-induced inhibition of platelet aggregation. Am Heart J1985; 109: 1258–1263.
32.
MoschosCBHaiderBKhenYRelation of platelets to catecholamines induced myocardial injury. Cardiovasc Res1978; 12: 243–246.
33.
HustedSEKraamer-NielsenHKrusellLRAcetylsalycilic acid 100 mg and 1000 mg daily in acute myocardial infarction suspects: a placebo-controlled trial. J Intern Med1989; 226: 303–310.
34.
The Canadian Cooperative Study Group: A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med1978; 229: 53–59.
